The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-(5-chloro-2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)-2-(2-(4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)-2-oxoethyl)isoindolin-1-one ID: ALA4847468
PubChem CID: 129077220
Max Phase: Preclinical
Molecular Formula: C29H30ClN5O3
Molecular Weight: 532.04
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: O=C(CN1Cc2ccc(-c3nc(NC4CCOCC4)ncc3Cl)cc2C1=O)N1CCCc2ccccc2C1
Standard InChI: InChI=1S/C29H30ClN5O3/c30-25-15-31-29(32-23-9-12-38-13-10-23)33-27(25)20-7-8-22-17-35(28(37)24(22)14-20)18-26(36)34-11-3-6-19-4-1-2-5-21(19)16-34/h1-2,4-5,7-8,14-15,23H,3,6,9-13,16-18H2,(H,31,32,33)
Standard InChI Key: IGCMZDAOWJBAOH-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 43 0 0 0 0 0 0 0 0999 V2000
21.0491 -9.5274 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.7654 -9.1141 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.7626 -8.2835 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.0472 -7.8745 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3342 -9.1146 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3355 -8.2857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.5476 -8.0283 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0593 -8.6982 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.5456 -9.3694 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.4770 -9.5246 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.4769 -10.3507 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.1912 -10.7620 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.9060 -10.3484 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.9021 -9.5191 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.1872 -9.1116 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.6144 -9.1030 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.3310 -9.5118 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.3303 -10.3381 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0428 -10.7470 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7575 -10.3343 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
26.7553 -9.5084 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0383 -9.0951 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.2343 -8.6970 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8228 -7.9819 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9978 -7.9808 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.2364 -7.2681 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
19.2895 -10.1537 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.6386 -8.7248 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.8326 -8.9094 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.6383 -7.2408 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.1863 -8.3987 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.1885 -7.5750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.8328 -7.0603 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7085 -6.2470 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9405 -5.9473 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2963 -6.4671 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.4239 -7.2785 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.7627 -10.7636 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
5 1 1 0
1 2 2 0
2 3 1 0
3 4 2 0
4 6 1 0
5 6 2 0
6 7 1 0
7 8 1 0
8 9 1 0
9 5 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 10 1 0
2 10 1 0
14 16 1 0
16 17 1 0
17 18 1 0
17 22 1 0
18 19 1 0
19 20 1 0
20 21 1 0
21 22 1 0
8 23 1 0
23 24 1 0
24 25 1 0
24 26 2 0
9 27 2 0
25 28 1 0
28 29 1 0
25 30 1 0
29 31 1 0
30 33 1 0
31 32 1 0
32 33 2 0
33 34 1 0
34 35 2 0
35 36 1 0
36 37 2 0
37 32 1 0
11 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 532.04Molecular Weight (Monoisotopic): 531.2037AlogP: 4.32#Rotatable Bonds: 5Polar Surface Area: 87.66Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 13.82CX Basic pKa: 2.33CX LogP: 3.18CX LogD: 3.18Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.53Np Likeness Score: -1.13
References 1. Heightman TD, Berdini V, Bevan L, Buck IM, Carr MG, Courtin A, Coyle JE, Day JEH, East C, Fazal L, Griffiths-Jones CM, Howard S, Kucia-Tran J, Martins V, Muench S, Munck JM, Norton D, O'Reilly M, Palmer N, Pathuri P, Peakman TM, Reader M, Rees DC, Rich SJ, Shah A, Wallis NG, Walton H, Wilsher NE, Woolford AJ, Cooke M, Cousin D, Onions S, Shannon J, Watts J, Murray CW.. (2021) Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2., 64 (16.0): [PMID:34387469 ] [10.1021/acs.jmedchem.1c00905 ]